Sanofi India Q2 FY26 Profit Up 19% to ₹112 Crore on Strong Diabetes Portfolio
Sanofi India reported Q2 FY26 profit before tax of ₹112 crore, a 19% increase year-on-year. Domestic net sales grew 8%, and total net sales grew 6%. The insulin portfolio saw 14% growth. The Board approved these results and re-constituted committees effective October 1, 2026, following Mr. Rachid Ayari's cessation as CFO on September 30, 2026.
The positive financial results and committee re-constitutions are material to the company's operations and governance, impacting investor outlook.
The company reported strong financial results with significant profit growth and double-digit growth in its key diabetes portfolio, alongside positive strategic and management updates.
Sanofi India Limited announced its unaudited financial results for the quarter and half-year ended June 30, 2026. The company reported a strong performance, with profits before tax and exceptional items increasing by 19% to ₹112 crore (1120 million) for the quarter, compared to ₹94 crore (940 million) in the same period last year. Profit before tax as a percentage of net sales improved to 27% from 24%.
The company's domestic net sales grew by 8% and total net sales by 6% year-on-year. The Insulin portfolio was a key driver, achieving double-digit growth of 14% for the second consecutive quarter, reinforcing Sanofi's leadership with a 58% value market share in the basal analog segment. Growth was attributed to Lantus®, Toujeo®, and Apidra®, along with Soliqua®.
The public sector business saw significant acceleration, growing by 70% due to new account openings for Toujeo® and Soliqua® under the CARE Accounts initiative. Partnership revenues grew by 2%, contributing to market reach expansion. Export sales remained stable.
In a board meeting held on August 4, 2026, the directors approved the unaudited financial results. The board also approved the re-constitution of the Stakeholders Relationship Committee and the Risk Management Committee, effective October 1, 2026. Furthermore, in light of Mr. Rachid Ayari stepping down as Whole Time Director and Chief Financial Officer on September 30, 2026, his name will be removed from the list of Key Managerial Personnels authorized for disclosures.
The Board meeting commenced at 4:00 p.m. and concluded at 6:58 p.m.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.